| A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer (NCT06410534) | National Cancer Institute (NCI) | 2025-09-09 |
| [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers (NCT06479811) | National Cancer Institute (NCI) | 2025-08-19 |
| Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes (NCT06484062) | National Cancer Institute (NCI) | 2025-08-15 |
| Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) (NCT06603818) | National Cancer Institute (NCI) | 2025-08-15 |
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) (NCT06661915) | National Cancer Institute (NCI) | 2025-08-14 |
| Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer (NCT06732401) | National Cancer Institute (NCI) | 2025-08-07 |
| Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer (NCT06590558) | National Cancer Institute (NCI) | 2025-08-04 |
| Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma (NCT06860594) | National Cancer Institute (NCI) | 2025-07-30 |
| Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction (NCT06195306) | National Cancer Institute (NCI) | 2025-07-28 |
| Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants (NCT07019155) | National Cancer Institute (NCI) | 2025-07-24 |
| Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors (NCT06161558) | National Cancer Institute (NCI) | 2025-07-15 |
| Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS (NCT05879484) | National Cancer Institute (NCI) | 2025-07-09 |
| Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma (NCT06885697) | National Cancer Institute (NCI) | 2025-07-08 |
| Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers (NCT06606990) | National Cancer Institute (NCI) | 2025-07-01 |
| Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy (NCT05237986) | National Cancer Institute (NCI) | 2025-06-23 |
| Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (NCT06696768) | National Cancer Institute (NCI) | 2025-06-23 |
| The Vanguard Study: Testing a New Way to Screen for Cancer (NCT06995898) | National Cancer Institute (NCI) | 2025-06-18 |
| Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) (NCT06577441) | National Cancer Institute (NCI) | 2025-06-12 |
| Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas (NCT06865677) | National Cancer Institute (NCI) | 2025-06-09 |
| Exploring How to Adapt an Evidence-Based Mindful Self-Compassion Program for Young Adults With Li-Fraumeni Syndrome (NCT07032922) | National Cancer Institute (NCI) | 2025-06-05 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (NCT06317662) | National Cancer Institute (NCI) | 2025-06-05 |
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (NCT06770582) | National Cancer Institute (NCI) | 2025-06-03 |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) (NCT06124157) | National Cancer Institute (NCI) | 2025-05-30 |
| Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) (NCT06672146) | National Cancer Institute (NCI) | 2025-05-16 |
| Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy (NCT06439836) | National Cancer Institute (NCI) | 2025-05-05 |
| Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma (NCT06328036) | National Cancer Institute (NCI) | 2025-04-30 |
| Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study (NCT06880991) | National Cancer Institute (NCI) | 2025-04-29 |
| Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer (NCT06654037) | National Cancer Institute (NCI) | 2025-04-18 |
| Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer (NCT06287775) | National Cancer Institute (NCI) | 2025-04-08 |
| Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial (NCT06498635) | National Cancer Institute (NCI) | 2025-04-01 |
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment (NCT06589804) | National Cancer Institute (NCI) | 2025-03-27 |
| Studying TAK-243 in Patients With Advanced Cancer (NCT06223542) | National Cancer Institute (NCI) | 2025-03-24 |
| Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) (NCT06311214) | National Cancer Institute (NCI) | 2025-03-18 |
| Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS) (NCT06052618) | National Cancer Institute (NCI) | 2025-03-17 |
| TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts (NCT03816319) | National Cancer Institute (NCI) | 2025-03-12 |
| Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer (NCT06568172) | National Cancer Institute (NCI) | 2025-02-18 |
| Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy (NCT06427798) | National Cancer Institute (NCI) | 2025-02-07 |
| Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors (NCT06364410) | National Cancer Institute (NCI) | 2025-02-03 |
| Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (NCT06514261) | National Cancer Institute (NCI) | 2024-12-18 |
| Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia (NCT06311227) | National Cancer Institute (NCI) | 2024-12-16 |
| Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma (NCT06465316) | National Cancer Institute (NCI) | 2024-12-06 |
| Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma (NCT06325683) | National Cancer Institute (NCI) | 2024-11-08 |
| Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors (NCT04890093) | National Cancer Institute (NCI) | 2024-10-31 |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma (NCT06337318) | National Cancer Institute (NCI) | 2024-10-23 |
| Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer (NCT05941520) | National Cancer Institute (NCI) | 2024-10-10 |
| Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST) (NCT06222203) | National Cancer Institute (NCI) | 2024-10-09 |
| Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma (NCT06344130) | National Cancer Institute (NCI) | 2024-10-01 |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) (NCT06317649) | National Cancer Institute (NCI) | 2024-09-27 |
| Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial (NCT06184750) | National Cancer Institute (NCI) | 2024-09-27 |
| Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) (NCT05554406) | National Cancer Institute (NCI) | 2024-09-25 |
| Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism (NCT06246357) | National Cancer Institute (NCI) | 2024-09-23 |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) (NCT05554393) | National Cancer Institute (NCI) | 2024-09-13 |
| Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) (NCT05554354) | National Cancer Institute (NCI) | 2024-09-13 |
| Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02) (NCT06611553) | National Cancer Institute (NCI) | 2024-09-13 |
| Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial (NCT06022822) | National Cancer Institute (NCI) | 2024-09-12 |
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas (NCT06422806) | National Cancer Institute (NCI) | 2024-09-11 |
| Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03) (NCT06611540) | National Cancer Institute (NCI) | 2024-09-11 |
| Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias (NCT06364423) | National Cancer Institute (NCI) | 2024-09-03 |
| Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma (NCT06179888) | National Cancer Institute (NCI) | 2024-08-27 |
| Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors (NCT05687123) | National Cancer Institute (NCI) | 2024-08-14 |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) (NCT06210750) | National Cancer Institute (NCI) | 2024-08-09 |
| Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer (NCT05898828) | National Cancer Institute (NCI) | 2024-08-02 |
| Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... (NCT06161532) | National Cancer Institute (NCI) | 2024-08-01 |
| Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) (NCT05638295) | National Cancer Institute (NCI) | 2024-08-01 |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (NCT05896839) | National Cancer Institute (NCI) | 2024-07-24 |
| Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (NCT06169215) | National Cancer Institute (NCI) | 2024-07-23 |
| Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (NCT06096844) | National Cancer Institute (NCI) | 2024-07-19 |
| Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (NCT06029270) | National Cancer Institute (NCI) | 2024-07-15 |
| Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery (NCT06050252) | National Cancer Institute (NCI) | 2024-07-10 |
| Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease (NCT05907759) | National Cancer Institute (NCI) | 2024-07-10 |
| Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01) (NCT06498661) | National Cancer Institute (NCI) | 2024-06-26 |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) (NCT06064097) | National Cancer Institute (NCI) | 2024-06-25 |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial (NCT06203600) | National Cancer Institute (NCI) | 2024-06-24 |
| A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease (NCT05886049) | National Cancer Institute (NCI) | 2024-06-20 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (NCT05564390) | National Cancer Institute (NCI) | 2024-06-18 |
| A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors (NCT06041516) | National Cancer Institute (NCI) | 2024-06-17 |
| Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) (NCT06228066) | National Cancer Institute (NCI) | 2024-06-13 |
| Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers (NCT05691517) | National Cancer Institute (NCI) | 2024-06-12 |
| Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (NCT06223568) | National Cancer Institute (NCI) | 2024-06-10 |
| Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors (NCT05687136) | National Cancer Institute (NCI) | 2024-06-07 |
| Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer (NCT06102902) | National Cancer Institute (NCI) | 2024-06-05 |
| Oral Iloprost for the Prevention of Lung Cancer In Former Smokers (NCT05411107) | National Cancer Institute (NCI) | 2024-06-01 |
| Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial (NCT05947500) | National Cancer Institute (NCI) | 2024-05-21 |
| Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT06015880) | National Cancer Institute (NCI) | 2024-05-20 |
| Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer (NCT06253520) | National Cancer Institute (NCI) | 2024-05-16 |
| Natural History Study of Kaposi Sarcoma (NCT06375122) | National Cancer Institute (NCI) | 2024-05-15 |
| Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer (NCT06253494) | National Cancer Institute (NCI) | 2024-05-14 |
| A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) (NCT05849480) | National Cancer Institute (NCI) | 2024-05-08 |
| Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) (NCT06126276) | National Cancer Institute (NCI) | 2024-05-07 |
| Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults With Sickle Cell Disease (SCD) (NCT05457790) | National Cancer Institute (NCI) | 2024-05-03 |
| Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) (NCT05665361) | National Cancer Institute (NCI) | 2024-04-24 |
| Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy (NCT06096870) | National Cancer Institute (NCI) | 2024-04-22 |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (NCT06172296) | National Cancer Institute (NCI) | 2024-04-19 |
| Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer (NCT05777603) | National Cancer Institute (NCI) | 2024-04-18 |
| N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer (NCT05445882) | National Cancer Institute (NCI) | 2024-04-01 |
| A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis (NCT05828069) | National Cancer Institute (NCI) | 2024-03-28 |
| Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) (NCT06149481) | National Cancer Institute (NCI) | 2024-03-26 |
| 18F-Fluciclovine PET/CT in Multiple Myeloma (NCT06103838) | National Cancer Institute (NCI) | 2024-03-25 |
| Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy (NCT05872503) | National Cancer Institute (NCI) | 2024-03-20 |
| Non-Viral TCR Gene Therapy (NCT04102436) | National Cancer Institute (NCI) | 2024-03-08 |